Roche CD20/CD3 bispecific antibody starts clinical trials in China

ArticleMedicine Guanlan

According to the Chinese drug clinical trial registration and information disclosure platform, Roche has initiated a phase 1 clinical study of RO7030816 (mosunetuzumab) in the treatment of patients with relapsed or refractory follicular lymphoma in China

Screenshot source: Drug clinical trial registration and information disclosure platform

Bispecific antibody therapy is a method of using T cells in the patient's immune system to kill tumors

As a bispecific antibody, one end of mosunetuzumab can bind to the CD20 antigen on the surface of B cells, and the other end binds to the CD3 receptor on the surface of T cells, recruiting T cells to the vicinity of tumor cells, activating T cells to kill tumor cells

Roche initiated an open, multi-center, phase 1 clinical trial to evaluate the pharmacokinetics, safety and effectiveness of mosunetuzumab monotherapy in patients with relapsed or refractory follicular lymphoma

According to the information of the Chinese drug clinical trial registration and information disclosure platform, the purpose of the phase 1 clinical trial mainly includes: ①characterizing the PK characteristics of mosunetuzumab; ②evaluating the safety, tolerability, effectiveness and immune response of mosunetuzumab monotherapy

Follicular lymphoma (FL) is a common type of indolent B-cell lymphoma and a type of indolent non-Hodgkin's lymphoma (NHL)

references:

[1] China Drug Clinical Trial Registration and Information Disclosure Platform.